<?xml version='1.0' encoding='utf-8'?>
<document id="22259019"><sentence text="Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin."><entity charOffset="65-76" id="DDI-PubMed.22259019.s1.e0" text="N-carbamoyl" /><entity charOffset="96-106" id="DDI-PubMed.22259019.s1.e1" text="lorcaserin" /><pair ddi="false" e1="DDI-PubMed.22259019.s1.e0" e2="DDI-PubMed.22259019.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22259019.s1.e0" e2="DDI-PubMed.22259019.s1.e1" /></sentence><sentence text="Lorcaserin, a selective serotonin 5-HT(2C) receptor agonist, is a weight management agent in clinical development"><entity charOffset="0-10" id="DDI-PubMed.22259019.s2.e0" text="Lorcaserin" /><entity charOffset="24-33" id="DDI-PubMed.22259019.s2.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.22259019.s2.e0" e2="DDI-PubMed.22259019.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22259019.s2.e0" e2="DDI-PubMed.22259019.s2.e1" /></sentence><sentence text=" Lorcaserin N-carbamoyl glucuronidation governs the predominant excretory pathway of lorcaserin in humans"><entity charOffset="1-23" id="DDI-PubMed.22259019.s3.e0" text="Lorcaserin N-carbamoyl" /><entity charOffset="85-95" id="DDI-PubMed.22259019.s3.e1" text="lorcaserin" /><pair ddi="false" e1="DDI-PubMed.22259019.s3.e0" e2="DDI-PubMed.22259019.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22259019.s3.e0" e2="DDI-PubMed.22259019.s3.e1" /></sentence><sentence text=" Human UDP-glucuronosyltransferases (UGTs) responsible for lorcaserin N-carbamoyl glucuronidation are identified herein"><entity charOffset="59-81" id="DDI-PubMed.22259019.s4.e0" text="lorcaserin N-carbamoyl" /></sentence><sentence text=" Lorcaserin N-carbamoyl glucuronide formation was characterized by the following approaches: metabolic screening using human tissues (liver, kidney, intestine, and lung) and recombinant enzymes, kinetic analyses, and inhibition studies"><entity charOffset="1-35" id="DDI-PubMed.22259019.s5.e0" text="Lorcaserin N-carbamoyl glucuronide" /></sentence><sentence text=" Whereas microsomes from all human tissues studied herein were found to be catalytically active for lorcaserin N-carbamoyl glucuronidation, liver microsomes were the most efficient"><entity charOffset="100-122" id="DDI-PubMed.22259019.s6.e0" text="lorcaserin N-carbamoyl" /></sentence><sentence text=" With recombinant UGT enzymes, lorcaserin N-carbamoyl glucuronidation was predominantly catalyzed by three UGT2Bs (UGT2B7, UGT2B15, and UGT2B17), whereas two UGT1As (UGT1A6 and UGT1A9) played a minor role"><entity charOffset="31-53" id="DDI-PubMed.22259019.s7.e0" text="lorcaserin N-carbamoyl" /></sentence><sentence text=" UGT2B15 was most efficient, with an apparent K(m) value of 51" /><sentence text="6 ± 1" /><sentence text="9 μM and V(max) value of 237" /><sentence text="4 ± 2" /><sentence text="8 pmol/mg protein/min" /><sentence text=" The rank order of catalytic efficiency of human UGT enzymes for lorcaserin N-carbamoyl glucuronidation was UGT2B15 &gt; UGT2B7 &gt; UGT2B17 &gt; UGT1A9 &gt; UGT1A6"><entity charOffset="65-87" id="DDI-PubMed.22259019.s13.e0" text="lorcaserin N-carbamoyl" /></sentence><sentence text=" Inhibition of lorcaserin N-carbamoyl glucuronidation activities of UGT2B7, UGT2B15, and UGT2B17 in human liver microsomes by mefenamic acid, bisphenol A, and eugenol further substantiated the involvement of these UGT2B isoforms"><entity charOffset="15-37" id="DDI-PubMed.22259019.s14.e0" text="lorcaserin N-carbamoyl" /><entity charOffset="126-140" id="DDI-PubMed.22259019.s14.e1" text="mefenamic acid" /><entity charOffset="142-153" id="DDI-PubMed.22259019.s14.e2" text="bisphenol A" /><entity charOffset="159-166" id="DDI-PubMed.22259019.s14.e3" text="eugenol" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e0" e2="DDI-PubMed.22259019.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e0" e2="DDI-PubMed.22259019.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e0" e2="DDI-PubMed.22259019.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e0" e2="DDI-PubMed.22259019.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e1" e2="DDI-PubMed.22259019.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e1" e2="DDI-PubMed.22259019.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e1" e2="DDI-PubMed.22259019.s14.e3" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e2" e2="DDI-PubMed.22259019.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22259019.s14.e2" e2="DDI-PubMed.22259019.s14.e3" /></sentence><sentence text=" In conclusion, multiple human UGT enzymes catalyze N-carbamoyl glucuronidation of lorcaserin; therefore, it is unlikely that inhibition of any one of these UGT activities will lead to significant inhibition of the lorcaserin N-carbamoyl glucuronidation pathway"><entity charOffset="52-63" id="DDI-PubMed.22259019.s15.e0" text="N-carbamoyl" /><entity charOffset="83-93" id="DDI-PubMed.22259019.s15.e1" text="lorcaserin" /><entity charOffset="215-237" id="DDI-PubMed.22259019.s15.e2" text="lorcaserin N-carbamoyl" /><pair ddi="false" e1="DDI-PubMed.22259019.s15.e0" e2="DDI-PubMed.22259019.s15.e0" /><pair ddi="false" e1="DDI-PubMed.22259019.s15.e0" e2="DDI-PubMed.22259019.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22259019.s15.e0" e2="DDI-PubMed.22259019.s15.e2" /><pair ddi="false" e1="DDI-PubMed.22259019.s15.e1" e2="DDI-PubMed.22259019.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22259019.s15.e1" e2="DDI-PubMed.22259019.s15.e2" /></sentence><sentence text=" Thus, the potential for drug-drug interaction by concomitant administration of a drug(s) that is metabolized by any of these UGTs is remote" /><sentence text="" /></document>